, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Adjuvant therapy for pancreatic cancer: to treat or not to treat?

Berlin JD
Oncology (Williston Park). 2007 21 (6): 712-8; discussion 720, 725-6, 730

PMID: 17564327

Despite attempted curative resection of localized adenocarcinoma of the pancreas, most patients experience a recurrence and die of their disease. The Gastrointestinal Tumor Study Group, European Organisation for Research and Treatment of Cancer, and European Study Group for Pancreatic Cancer trials have suggested the benefit of adjuvant therapy. However, the relatively few randomized trials available have not established a definite standard of care due to study limitations. Although these trials, and the recently published Chariti Onkologie (CONKO)-001 trial, have shown a definite advantage of adjuvant chemotherapy, the most effective chemotherapy and the role of radiation therapy remain unclear. This review will discuss the data available from reported trials of adjuvant and neoadjuvant therapy in pancreatic cancer, address the issues leading to the ongoing controversies, and consider future directions for clinical trials.

MeSH Terms (10)

Adenocarcinoma Antimetabolites, Antineoplastic Antineoplastic Combined Chemotherapy Protocols Fluorouracil Humans Meta-Analysis as Topic Neoadjuvant Therapy Neoplasm Recurrence, Local Pancreatic Neoplasms Radiotherapy, Adjuvant

Connections (1)

This publication is referenced by other Labnodes entities: